<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03260790</url>
  </required_header>
  <id_info>
    <org_study_id>16-007731</org_study_id>
    <nct_id>NCT03260790</nct_id>
  </id_info>
  <brief_title>Pneumococcal Vaccines in Patients With Asthma</brief_title>
  <official_title>Immunogenicity of PPSV-23 After PCV-13 Vaccination in Adult Asthmatic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators are assessing if patients with asthma respond better to the Pneumovax vaccine&#xD;
      if they are given Prevnar initially.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized into either PCV13 and PPSV23 (Experimental) or PPSV23 alone&#xD;
      (Active comparator). At the Week 0 time point, the patients will receive either PCV13&#xD;
      (Experimental) or PPSV23 (Active comparator) and undergo a blood draw of 5ml for assessment&#xD;
      of pre-vacation serotype titers. The Active Comparator group will undergo a 5ml draw of blood&#xD;
      for assessment of titers at week 8, 16, and 24 following vaccination. The Experimental group&#xD;
      will undergo vaccination with PPSV23 at week 8 with 5 ml blood draw for pneumococcal serotype&#xD;
      titers as well as a blood draw at week 16 and week 24.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Actual">December 25, 2020</completion_date>
  <primary_completion_date type="Actual">December 21, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Anti-pneumococcal IgG Levels at Baseline, Week 0, Week 8 and Week 16</measure>
    <time_frame>Baseline, week 0, week 8, week 16</time_frame>
    <description>5 ml blood draw for assessment of pneumococcal specific titer IgG. Measured as mcg/dL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sum of Anti-pneumococcal IgG to All Serotypes at Baseline, Week 0, Week 8 and Week 16</measure>
    <time_frame>Baseline, week 0, week 8, week 16</time_frame>
    <description>5 ml blood draw for assessment of IgG specific Antibody titers to all 23 serotypes. Measured as mcg/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sum of Anti-pneumococcal IgG to Serotypes Common to PCV13 and PPSV23 at Baseline, Week 0, Week 8, Week 16</measure>
    <time_frame>Baseline, week 0, week 8, week 16</time_frame>
    <description>5 ml blood draw for assessment of IgG specific Antibody titers for serotypes common PCV13 &amp; PPSV23. Measured as mcg/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sum of Anti-pneumococcal IgG to Serotypes Unique to PPSV23 at Baseline, Week 0, Week 8 and Week 16.</measure>
    <time_frame>Baseline, week 0, week 8, week 16</time_frame>
    <description>5 ml blood draw for assessment of IgG specific Antibody titers for serotypes unique to PPSV23. Measured as mcg/mL.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>PCV13 and PPSV23</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive PPSV23 primed with PCV13. Participants will receive PCV13 8 weeks prior to receiving PPSV23</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PPSV23</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to receive PPSV23 alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PCV13</intervention_name>
    <description>Single 0.5 ml dose of PCV13 administered via intramuscular injection</description>
    <arm_group_label>PCV13 and PPSV23</arm_group_label>
    <other_name>Prevnar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PPSV23</intervention_name>
    <description>Single 0.5 ml dose of PPSV23 administered via intramuscularly or subcutaneously</description>
    <arm_group_label>PCV13 and PPSV23</arm_group_label>
    <arm_group_label>PPSV23</arm_group_label>
    <other_name>Pneumovax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Diagnosis of asthma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Research exemption requested&#xD;
&#xD;
          -  History of PCV-13 vaccination&#xD;
&#xD;
          -  History of cochlear implant&#xD;
&#xD;
          -  Cerebrospinal Fluid (CSF) leak&#xD;
&#xD;
          -  Congestive Heart Failure (CHF)&#xD;
&#xD;
          -  Diabetes Mellitus (DM)&#xD;
&#xD;
          -  Chronic Kidney Disease (CKD)&#xD;
&#xD;
          -  Human Immunodeficiency Virus (HIV)&#xD;
&#xD;
          -  Common Variable Immune Deficiency (CVID)&#xD;
&#xD;
          -  Patients who have received the PPSV23 vaccine in the last 5 years&#xD;
&#xD;
          -  Women who are pregnant will also be excluded from the study by performing 2 point of&#xD;
             care urine pregnancy tests ( prior to vaccinations)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Avni Y Joshi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 31, 2017</study_first_submitted>
  <study_first_submitted_qc>August 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2017</study_first_posted>
  <results_first_submitted>October 7, 2021</results_first_submitted>
  <results_first_submitted_qc>October 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 5, 2021</results_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Avni Joshi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <keyword>Pneumococcal</keyword>
  <keyword>Pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 7, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT03260790/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PCV13 and PPSV23</title>
          <description>Participants received PPSV23 primed with PCV13. Participants received PCV13 8 weeks prior to receiving PPSV23&#xD;
PCV13: Single 0.5 ml dose of PCV13 administered via intramuscular injection&#xD;
PPSV23: Single 0.5 ml dose of PPSV23 administered 8 weeks after receiving PCV13 via intramuscularly or subcutaneously</description>
        </group>
        <group group_id="P2">
          <title>PPSV23</title>
          <description>Participants received PPSV23 alone&#xD;
PPSV23: Single 0.5 ml dose of PPSV23 administered via intramuscularly or subcutaneously</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PCV13 and PPSV23</title>
          <description>Participants received PPSV23 primed with PCV13. Participants received PCV13 8 weeks prior to receiving PPSV23&#xD;
PCV13: Single 0.5 ml dose of PCV13 administered via intramuscular injection&#xD;
PPSV23: Single 0.5 ml dose of PPSV23 administered 8 weeks after receiving PCV13 via intramuscularly or subcutaneously</description>
        </group>
        <group group_id="B2">
          <title>PPSV23</title>
          <description>Participants received PPSV23 alone&#xD;
PPSV23: Single 0.5 ml dose of PPSV23 administered via intramuscularly or subcutaneously</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Anti-pneumococcal IgG Levels at Baseline, Week 0, Week 8 and Week 16</title>
        <description>5 ml blood draw for assessment of pneumococcal specific titer IgG. Measured as mcg/dL.</description>
        <time_frame>Baseline, week 0, week 8, week 16</time_frame>
        <population>Baseline = For arm PPSV23 baseline is 8 weeks prior to receiving PPSV-23. For arm PCV13 and PPSV23 baseline is day of receiving PCV-13. Week 0 = day of receiving PPSV-23 for both arms. Week 8 = eight weeks after receiving PPSV-23 for both arms. Week 16 = sixteen weeks after receiving PPSV-23 for both arms.</population>
        <group_list>
          <group group_id="O1">
            <title>PCV13 and PPSV23</title>
            <description>Participants received PPSV23 primed with PCV13. Participants received PCV13 8 weeks prior to receiving PPSV23&#xD;
PCV13: Single 0.5 ml dose of PCV13 administered via intramuscular injection&#xD;
PPSV23: Single 0.5 ml dose of PPSV23 administered 8 weeks after receiving PCV13 via intramuscularly or subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>PPSV23</title>
            <description>Participants received PPSV23 alone&#xD;
PPSV23: Single 0.5 ml dose of PPSV23 administered via intramuscularly or subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Total Anti-pneumococcal IgG Levels at Baseline, Week 0, Week 8 and Week 16</title>
          <description>5 ml blood draw for assessment of pneumococcal specific titer IgG. Measured as mcg/dL.</description>
          <population>Baseline = For arm PPSV23 baseline is 8 weeks prior to receiving PPSV-23. For arm PCV13 and PPSV23 baseline is day of receiving PCV-13. Week 0 = day of receiving PPSV-23 for both arms. Week 8 = eight weeks after receiving PPSV-23 for both arms. Week 16 = sixteen weeks after receiving PPSV-23 for both arms.</population>
          <units>mcg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.8" lower_limit="74.3" upper_limit="141.8"/>
                    <measurement group_id="O2" value="53.9" lower_limit="34.8" upper_limit="185.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.3" lower_limit="111.7" upper_limit="194.6"/>
                    <measurement group_id="O2" value="53.9" lower_limit="34.8" upper_limit="185.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="211.7" lower_limit="184.6" upper_limit="271.0"/>
                    <measurement group_id="O2" value="243.3" lower_limit="173.4" upper_limit="271.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212.0" lower_limit="171.1" upper_limit="257.7"/>
                    <measurement group_id="O2" value="224.8" lower_limit="196.6" upper_limit="271.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sum of Anti-pneumococcal IgG to All Serotypes at Baseline, Week 0, Week 8 and Week 16</title>
        <description>5 ml blood draw for assessment of IgG specific Antibody titers to all 23 serotypes. Measured as mcg/mL.</description>
        <time_frame>Baseline, week 0, week 8, week 16</time_frame>
        <population>Baseline = For arm PPSV23 baseline is 8 weeks prior to receiving PPSV-23. For arm PCV13 and PPSV23 baseline is day of receiving PCV-13. Week 0 = day of receiving PPSV-23 for both arms. Week 8 = eight weeks after receiving PPSV-23 for both arms. Week 16 = sixteen weeks after receiving PPSV-23 for both arms.</population>
        <group_list>
          <group group_id="O1">
            <title>PCV13 and PPSV23</title>
            <description>Participants received PPSV23 primed with PCV13. Participants received PCV13 8 weeks prior to receiving PPSV23&#xD;
PCV13: Single 0.5 ml dose of PCV13 administered via intramuscular injection&#xD;
PPSV23: Single 0.5 ml dose of PPSV23 administered 8 weeks after receiving PCV13 via intramuscularly or subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>PPSV23</title>
            <description>Participants received PPSV23 alone&#xD;
PPSV23: Single 0.5 ml dose of PPSV23 administered via intramuscularly or subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Sum of Anti-pneumococcal IgG to All Serotypes at Baseline, Week 0, Week 8 and Week 16</title>
          <description>5 ml blood draw for assessment of IgG specific Antibody titers to all 23 serotypes. Measured as mcg/mL.</description>
          <population>Baseline = For arm PPSV23 baseline is 8 weeks prior to receiving PPSV-23. For arm PCV13 and PPSV23 baseline is day of receiving PCV-13. Week 0 = day of receiving PPSV-23 for both arms. Week 8 = eight weeks after receiving PPSV-23 for both arms. Week 16 = sixteen weeks after receiving PPSV-23 for both arms.</population>
          <units>mcg/mL.</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228.0" lower_limit="174.2" upper_limit="362.3"/>
                    <measurement group_id="O2" value="206.8" lower_limit="130.1" upper_limit="323.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="506.3" lower_limit="349.6" upper_limit="670.9"/>
                    <measurement group_id="O2" value="206.8" lower_limit="130.1" upper_limit="323.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="502.9" lower_limit="369.9" upper_limit="790.5"/>
                    <measurement group_id="O2" value="449.4" lower_limit="338.7" upper_limit="583.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="534.8" lower_limit="325.4" upper_limit="688.4"/>
                    <measurement group_id="O2" value="485.7" lower_limit="321.2" upper_limit="588.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sum of Anti-pneumococcal IgG to Serotypes Common to PCV13 and PPSV23 at Baseline, Week 0, Week 8, Week 16</title>
        <description>5 ml blood draw for assessment of IgG specific Antibody titers for serotypes common PCV13 &amp; PPSV23. Measured as mcg/mL.</description>
        <time_frame>Baseline, week 0, week 8, week 16</time_frame>
        <population>Baseline = For arm PPSV23 baseline is 8 weeks prior to receiving PPSV-23. For arm PCV13 and PPSV23 baseline is day of receiving PCV-13. Week 0 = day of receiving PPSV-23 for both arms. Week 8 = eight weeks after receiving PPSV-23 for both arms. Week 16 = sixteen weeks after receiving PPSV-23 for both arms.</population>
        <group_list>
          <group group_id="O1">
            <title>PCV13 and PPSV23</title>
            <description>Participants received PPSV23 primed with PCV13. Participants received PCV13 8 weeks prior to receiving PPSV23&#xD;
PCV13: Single 0.5 ml dose of PCV13 administered via intramuscular injection&#xD;
PPSV23: Single 0.5 ml dose of PPSV23 administered 8 weeks after receiving PCV13 via intramuscularly or subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>PPSV23</title>
            <description>Participants received PPSV23 alone&#xD;
PPSV23: Single 0.5 ml dose of PPSV23 administered via intramuscularly or subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Sum of Anti-pneumococcal IgG to Serotypes Common to PCV13 and PPSV23 at Baseline, Week 0, Week 8, Week 16</title>
          <description>5 ml blood draw for assessment of IgG specific Antibody titers for serotypes common PCV13 &amp; PPSV23. Measured as mcg/mL.</description>
          <population>Baseline = For arm PPSV23 baseline is 8 weeks prior to receiving PPSV-23. For arm PCV13 and PPSV23 baseline is day of receiving PCV-13. Week 0 = day of receiving PPSV-23 for both arms. Week 8 = eight weeks after receiving PPSV-23 for both arms. Week 16 = sixteen weeks after receiving PPSV-23 for both arms.</population>
          <units>mcg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.4" lower_limit="110.7" upper_limit="246.8"/>
                    <measurement group_id="O2" value="107.4" lower_limit="92.9" upper_limit="161.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="418.9" lower_limit="303.2" upper_limit="525.1"/>
                    <measurement group_id="O2" value="107.4" lower_limit="92.9" upper_limit="161.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="362.8" lower_limit="258.9" upper_limit="498.6"/>
                    <measurement group_id="O2" value="229.4" lower_limit="162.6" upper_limit="302.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="343.7" lower_limit="221.5" upper_limit="447.1"/>
                    <measurement group_id="O2" value="230.5" lower_limit="149.5" upper_limit="302.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sum of Anti-pneumococcal IgG to Serotypes Unique to PPSV23 at Baseline, Week 0, Week 8 and Week 16.</title>
        <description>5 ml blood draw for assessment of IgG specific Antibody titers for serotypes unique to PPSV23. Measured as mcg/mL.</description>
        <time_frame>Baseline, week 0, week 8, week 16</time_frame>
        <population>Baseline = For arm PPSV23 baseline is 8 weeks prior to receiving PPSV-23. For arm PCV13 and PPSV23 baseline is day of receiving PCV-13. Week 0 = day of receiving PPSV-23 for both arms. Week 8 = eight weeks after receiving PPSV-23 for both arms. Week 16 = sixteen weeks after receiving PPSV-23 for both arms.</population>
        <group_list>
          <group group_id="O1">
            <title>PCV13 and PPSV23</title>
            <description>Participants received PPSV23 primed with PCV13. Participants received PCV13 8 weeks prior to receiving PPSV23&#xD;
PCV13: Single 0.5 ml dose of PCV13 administered via intramuscular injection&#xD;
PPSV23: Single 0.5 ml dose of PPSV23 administered 8 weeks after receiving PCV13 via intramuscularly or subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>PPSV23</title>
            <description>Participants received PPSV23 alone&#xD;
PPSV23: Single 0.5 ml dose of PPSV23 administered via intramuscularly or subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Sum of Anti-pneumococcal IgG to Serotypes Unique to PPSV23 at Baseline, Week 0, Week 8 and Week 16.</title>
          <description>5 ml blood draw for assessment of IgG specific Antibody titers for serotypes unique to PPSV23. Measured as mcg/mL.</description>
          <population>Baseline = For arm PPSV23 baseline is 8 weeks prior to receiving PPSV-23. For arm PCV13 and PPSV23 baseline is day of receiving PCV-13. Week 0 = day of receiving PPSV-23 for both arms. Week 8 = eight weeks after receiving PPSV-23 for both arms. Week 16 = sixteen weeks after receiving PPSV-23 for both arms.</population>
          <units>mcg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.2" lower_limit="64.1" upper_limit="120.9"/>
                    <measurement group_id="O2" value="74.7" lower_limit="41.0" upper_limit="160.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.4" lower_limit="56.2" upper_limit="152.4"/>
                    <measurement group_id="O2" value="74.7" lower_limit="41.0" upper_limit="160.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174.2" lower_limit="92.3" upper_limit="283.4"/>
                    <measurement group_id="O2" value="220.0" lower_limit="164.7" upper_limit="246.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179.1" lower_limit="96.9" upper_limit="277.0"/>
                    <measurement group_id="O2" value="184.1" lower_limit="171.0" upper_limit="255.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collected from baseline to end of study, approximately 16 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PCV13 and PPSV23</title>
          <description>Participants received PPSV23 primed with PCV13&#xD;
PCV13: Single 0.5 ml dose of PCV13 administered via intramuscular injection&#xD;
PPSV23: Single 0.5 ml dose of PPSV23 administered 8 weeks after receiving PCV13 via intramuscularly or subcutaneously</description>
        </group>
        <group group_id="E2">
          <title>PPSV23</title>
          <description>Participants received PPSV23 alone&#xD;
PPSV23: Single 0.5 ml dose of PPSV23 administered via intramuscularly or subcutaneously</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Avni Y. Joshi, M.D., M.S.</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-284-3165</phone>
      <email>Joshi.Avni@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

